Taysha Gene Therapies (TSHA) Stock Price Surges 343.45% From Year Ago Levels

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The stock is up 343.45% from its price a year ago and 22.48% year-to-date. On April 15, Needham reiterated its buy rating for Taysha Gene Therapies with a price target of $12.

Earlier on April 6, Canaccord Genuity also reiterated its buy rating for Taysha Gene Therapies, raising its price target to $17 from $14.

Is enGene Holdings Inc. (ENGN) the Best Canadian Penny Stock to Invest in Now?

On April 3, Taysha Gene Therapies announced that the Compensation Committee of its Board of Directors granted four new employees, in the aggregate, restricted stock units (RSUs) representing 300,000 shares of the company’s common stock and an option to purchase 92,400 shares of the company’s common stock in connection with their employment. The RSUs and stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

Taysha Gene Therapies (NASDAQ:TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program, TSHA-102, is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease.

While we acknowledge the risk and potential of TSHA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TSHA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Data Center Stocks to Buy for the Long Term and 8 Must-Buy Small Cap Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.